Literature DB >> 34922148

DDX56 antagonizes IFN-β production to enhance EMCV replication by inhibiting IRF3 nuclear translocation.

Shujuan Xu1, Jingying Xie1, Xiangbo Zhang1, Lei Chen1, Yingjie Bi1, Xiangrong Li1, Adi Idris2, Ruofei Feng3.   

Abstract

DEAD (Asp-Glu-Ala-Asp)-box RNA helicases (DDX) play important roles in viral infection, either as cytosolic viral nucleic acids sensors or as essential host factors for viral replication. In this study, we identified DDX56 as a positive regulator for encephalomyocarditis virus (EMCV) replication. EMCV infection promotes DDX56 expression via its viral proteins, VP3 and 3C. We showed that DDX56 overexpression promotes EMCV replication whereas its loss dampened EMCV replication. Consequently, knockdown of DDX56 increases type I interferon (IFN) expression during EMCV infection. We also showed that DDX56 interrupts IFN regulatory factor 3 (IRF3) phosphorylation and its nucleus translocation by directly targeting KPNA3 and KPNA4 in an EMCV-triggered MDA5 signaling activation cascade leading to the blockade of IFN-β production. Overall, we showed that DDX56 is a novel negative regulator of EMCV-mediated IFN-β responses and that DDX56 plays a critical role in EMCV replication. These findings reveal a novel strategy for EMCV to utilize a host factor to evade the host innate immune response and provide us new insight into the function of DDX56.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DDX56; EMCV; IFN-β signaling pathway; IRF3

Mesh:

Substances:

Year:  2021        PMID: 34922148     DOI: 10.1016/j.vetmic.2021.109304

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  1 in total

1.  DDX56 inhibits PRV replication through regulation of IFN-β signaling pathway by targeting cGAS.

Authors:  Jingying Xie; Xiangrong Li; Shunyu Yang; Zhenfang Yan; Lei Chen; Yanmei Yang; Dianyu Li; Xiangbo Zhang; Ruofei Feng
Journal:  Front Microbiol       Date:  2022-08-10       Impact factor: 6.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.